Research & Development

Our people

Home / Our company / Our people / Research & Development

Jump to

At AstraZeneca, we focus on the discovery, development and commercialisation of prescription medicines in Oncology, BioPharmaceuticals and Rare Disease, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Our R&D groups are unified in their approach, and united in their purpose to deliver life-changing medicines to people who need them most. By collaborating internally and externally, we aim to accelerate the discovery of novel therapies for unmet medical needs.

BioPharmaceuticals R&D

Adam Platt

VP and Head of Translational Science and Experimental Medicine, Respiratory and Immunology, AstraZeneca
Amy Taylor

Business Planning & Operations Director, Chief Operating Office, BioPharmaceuticals R&D
Ben Challis

VP and Head of Translational Science & Experimental Medicine, Cardiovascular, Renal and Metabolism, AstraZeneca

Oncology R&D

Anas Younes

Senior Vice President, Global Head of Haematology (Early and Late Stage) Oncology R&D
Andrew Foxley

Vice President, Franchise Head, Late Oncology R&D
Cristian Massacesi

Chief Medical Officer and Oncology Chief Development Officer

R&D

Alan Sabirsh

Principal Scientist, Advanced Drug Delivery, Pharmaceutical Sciences, R&D
Anna Åsberg

Vice President, R&D IT
Annette Bak

Head of Advanced Drug Delivery, Pharmaceutical Sciences, R&D

Explore our people in other business units

Oncology
BioPharmaceutical
Rare Disease
Enabling Functions
Operations
International

Veeva ID: Z4-70896
Date of preparation: December 2024